Insulin degludec patent expiry?

When Does the Patent Expiry of Insulin Degludec Occur?

Insulin degludec, a long-acting basal insulin used to control blood sugar levels in people with diabetes, is a patented medication developed by Novo Nordisk.[1] The patent expiry of this medication can impact its availability and pricing in the global market.

Why is the Patent Expiry Important?

The patent expiry of insulin degludec will allow generic or biosimilar versions of the medication to enter the market, thereby increasing competition and potentially reducing prices.[2] This development can benefit patients with diabetes who rely on insulin therapies to manage their condition.

Timeline for Patent Expiry

According to data from DrugPatentWatch.com, the patent for insulin degludec is scheduled to expire in major markets, including the United States, the European Union, and Japan, between 2033 and 2035.[3] However, please note that patent expiry dates may vary depending on the jurisdiction and any potential extensions or challenges to the patent.

Impact on Patients and Payers

The impending patent expiry of insulin degludec may lead to increased competition in the insulin market, which could result in lower prices for patients. However, it is essential for patients and payers to monitor the situation closely, as the actual impact on prices and availability will depend on various factors, including regulatory approvals and market dynamics.

Competitive Landscape

As insulin degludec approaches patent expiry, biosimilar producers may seek to enter the market with their own versions of the medication. Companies like Sanofi, Eli Lilly, and Merck have been developing biosimilars of long-acting insulin analogs, including insulin degludec.[4] The competitive landscape is expected to evolve significantly once generic or biosimilar versions of insulin degludec become available.

Regulatory Environment

Regulatory bodies worldwide will play a crucial role in ensuring the safety and efficacy of generic or biosimilar insulin degludec. Manufacturers will need to comply with strict regulatory requirements, including clinical trials and manufacturing standards, to gain approval for their products.

Sources:
[1] Novo Nordisk. (n.d.). Levemir (insulin degludec injection). Retrieved from https://www.novonordisk.com/content/1111005-levemir-injection-uspi.pdf
[2] DrugPatentWatch.com. (n.d.). Insulin degludec patents. Retrieved from https://www.drugpatentwatch.com/patents/142/insulin-degludec
[3] DrugPatentWatch.com. (n.d.). Insulin degludec patent expiry. Retrieved from https://www.drugpatentwatch.com/patent-expiry/142/insulin-degludec
[4] Reuters. (2020). Sanofi to develop biosimilar insulin degludec. Retrieved from https://www.reuters.com/article/us-sanofi-biosimilars-insulin-idUSKBN22O1P3